In contrast, HER2 positivity (p = 0.933), Ki-67 index (p = 0.782), and other clinical parameters—including BMI, smoking status, comorbidities, neoadjuvant chemotherapy, tumor size (pT), and nodal status (pN)—showed no significant effect. The gene discussed is ERBB2; the disease is neoplasm.